Skip to content

OÜ CentralPharma Communications

Registry code (registrikood) 10640025Private limited company (Osaühing)VAT EE100629860Activity (EMTAK 70201): Äri- ja muu juhtimisalane nõustamineActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€1.2M
▲ 9.2% vs 2024
Profit before tax (2025)
€280k
Employees, FTE (2025)
5
State taxes paid, last 4 quarters
€139k

Revenue, profit and employees, 2019–2025

€728k2019€731k2020€895k2021€1.2M2022€1.0M2023€1.1M2024€1.2M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€728,477€283,714€267,829€1,461,0305
2020€731,092€246,854€219,929€1,620,9595
2021€894,830€430,607€407,394€1,968,3525
2022€1,153,895€344,703€338,180€2,306,5324
2023€1,049,615€313,634€299,365€259,6714
2024€1,140,298€205,777€180,076€389,7475
2025€1,245,324€279,769€279,596€669,3435

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€273,452€1,781,692€121,251€199,411€1,461,030
2020€227,307€2,056,336€162,200€273,177€1,620,959
2021€203,048€2,380,315€406,993€4,970€1,968,352
2022€414,521€2,745,912€198,859€240,521€2,306,532
2023€189,683€584,948€146,663€178,614€259,671
2024€109,415€552,356€162,609€0€389,747
2025€302,330€829,574€160,231—€669,343

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€28,867€24,547€321,4647
2022 Q2€26,250€17,107€272,7626
2022 Q3€24,552€16,708€350,5727
2022 Q4€16,668€16,699€389,6796
2023 Q1€22,662€17,521€377,9486
2023 Q2€16,894€16,148€299,0015
2023 Q3€23,603€20,255€336,3205
2023 Q4€23,419€20,408€389,9695
2024 Q1€25,259€22,999€430,8715
2024 Q2€22,652€21,291€336,9066
2024 Q3€27,342€25,015€451,2306
2024 Q4€26,180€22,922€413,4476
2025 Q1€30,245€24,536€435,3896
2025 Q2€27,531€25,814€373,8536
2025 Q3€29,173€27,829€368,8748
2025 Q4€30,273€31,477€458,1568
2026 Q1€39,312€29,456€554,1817
2026 Q2€35,457€29,998€382,7237
2026 Q3€34,000€31,578€236,7927

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ CentralPharma Communications reported revenue of €1,245,324.

The company closed the 2025 financial year with a net profit of €279,596.

Revenue increased by 9.2% from €1,140,298 in 2024 to €1,245,324 in 2025.

Revenue grew at a compound annual rate of 9.3% between 2019 and 2025.

Equity accounted for 80.7% of total assets of €829,574 at the end of the 2025 reporting period.

With 5 full-time-equivalent employees in 2025, revenue per employee was €249,065.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ CentralPharma Communications reported €1,631,852 in turnover.

EMTA recorded 7 employees for the quarter ending Q3 2026, compared with 5 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.